Literature DB >> 17684765

Treatment of gastroenteropancreatic neuroendocrine tumors.

U Plöckinger1, B Wiedenmann.   

Abstract

Neuroendocrine tumors are rare; thus, individual experience with the diagnosis and treatment of these tumors is mostly low, except in specialized centers. For histological diagnosis, standards have been described recently. Pathological classification and clinical staging influence diagnostic and therapeutic decisions. This chapter aims at demonstrating the importance of pathological and clinical classification of neuroendocrine tumors on therapeutic decisions, indicating the appropriate therapy for different stages of the disease. Surgical therapy will be discussed shortly, including palliative surgical strategies. However, the focus of the manuscript is medical therapy. Biotherapy, its effects, and remaining uncertainties are presented as well as different chemotherapeutic schemes. Finally, new options of palliative medical therapies like kinase inhibitors and anti-angiogenetic drugs will be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684765     DOI: 10.1007/s00428-007-0446-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  62 in total

Review 1.  Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Authors:  U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann
Journal:  Neuroendocrinology       Date:  2005-04-18       Impact factor: 4.914

2.  Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma.

Authors:  F Panzuto; M Di Fonzo; E Iannicelli; R Sciuto; C L Maini; G Capurso; M Milione; M S Cattaruzza; M Falconi; V David; V Ziparo; P Pederzoli; C Bordi; G Delle Fave
Journal:  Ann Oncol       Date:  2005-12-19       Impact factor: 32.976

3.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

4.  Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect?

Authors:  L Y Dirix; P B Vermeulen; H Fierens; B De Schepper; B Corthouts; A T Van Oosterom
Journal:  Anticancer Drugs       Date:  1996-02       Impact factor: 2.248

5.  Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.

Authors:  P Tomassetti; M Migliori; R Corinaldesi; L Gullo
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

6.  Slow-release lanreotide treatment in endocrine gastrointestinal tumors.

Authors:  P Tomassetti; M Migliori; L Gullo
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

7.  Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.

Authors:  E Rivera; J A Ajani
Journal:  Am J Clin Oncol       Date:  1998-02       Impact factor: 2.339

8.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors:  Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

9.  A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.

Authors:  M Di Bartolomeo; E Bajetta; A M Bochicchio; C Carnaghi; L Somma; V Mazzaferro; M Visini; V Gebbia; S Tumolo; P Ballatore
Journal:  Ann Oncol       Date:  1995-01       Impact factor: 32.976

10.  Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.

Authors:  M di Bartolomeo; E Bajetta; R Buzzoni; L Mariani; C Carnaghi; L Somma; N Zilembo; A di Leo
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

View more
  12 in total

Review 1.  Pathology of Neuroendocrine Tumours of the Female Genital Tract.

Authors:  Brooke E Howitt; Paul Kelly; W Glenn McCluggage
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

Review 2.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 4.  [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].

Authors:  M B Niederle; B Niederle
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

5.  [Neuroendocrine tumors of the stomach. Risk stratification and therapy].

Authors:  G Klöppel; H Scherübl
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

6.  Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells.

Authors:  Kristina B V Døssing; Christina Kjær; Jonas Vikeså; Tina Binderup; Ulrich Knigge; Michael D Culler; Andreas Kjær; Birgitte Federspiel; Lennart Friis-Hansen
Journal:  Genes (Basel)       Date:  2018-07-04       Impact factor: 4.096

7.  Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.

Authors:  Edward M Wolin; Barbara Jarzab; Barbro Eriksson; Thomas Walter; Christos Toumpanakis; Michael A Morse; Paola Tomassetti; Matthias M Weber; David R Fogelman; John Ramage; Donald Poon; Brian Gadbaw; Jiang Li; Janice L Pasieka; Abakar Mahamat; Fredrik Swahn; John Newell-Price; Wasat Mansoor; Kjell Öberg
Journal:  Drug Des Devel Ther       Date:  2015-09-03       Impact factor: 4.162

Review 8.  PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franziska Briest; Patricia Grabowski
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

9.  Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors.

Authors:  James C Yao; Jennifer A Chan; Alain C Mita; Madan G Kundu; Karina Hermosillo Reséndiz; Ke Hu; Shoba Ravichandran; Jonathan R Strosberg; Edward M Wolin
Journal:  Onco Targets Ther       Date:  2017-06-27       Impact factor: 4.147

10.  Report of metastatic ileal neuroendocrine tumor to the submandibular gland.

Authors:  David Forner; Peter Cho; Martin Bullock; Daniel Rayson; S Mark Taylor; Robert D Hart; Jonathan R Trites; Matthew H Rigby
Journal:  Int J Surg Case Rep       Date:  2018-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.